Pra­tia LLC, part of Hu­mane­va Group, to­day an­nounced the ac­qui­si­tion of a ma­jor­i­ty stake in P1 Tri­als, a U.S.-based ear­ly phase on­col­o­gy clin­i­cal re­search net­work.

P1 Tri­als, with its com­mu­ni­ty-based on­col­o­gy prac­tices in the states of WA, TX and IN, brings ad­vanced ear­ly-phase on­col­o­gy stud­ies clos­er to where pa­tients re­ceive care. The com­pa­ny en­ables com­mu­ni­ty on­col­o­gy prac­tices by pro­vid­ing the in­fra­struc­ture and sup­port need­ed to con­duct ear­ly-phase tri­als through a uni­fied glob­al stan­dard.

Through this in­vest­ment, Pra­tia and P1 are es­tab­lish­ing one of the few glob­al re­search ecosys­tems ded­i­cat­ed ex­clu­sive­ly to ear­ly-phase on­col­o­gy, con­nect­ing North Amer­i­ca and Eu­rope to ac­cel­er­ate the de­vel­op­ment of next-gen­er­a­tion can­cer treat­ments. Unit­ed by a shared mis­sion, Pra­tia and P1 Tri­als are deeply pa­tient-cen­tric, and will con­tin­ue work­ing to bring in­no­v­a­tive ther­a­pies to pa­tients wher­ev­er they live.

Pra­tia cur­rent­ly reach­es more than 65 mil­lion pa­tients across Eu­rope through its in­te­grat­ed on­col­o­gy re­search sites. The ad­di­tion of P1’s U.S. net­work ex­tends that reach and en­hances both com­pa­nies' abil­i­ty to de­liv­er in­no­v­a­tive stud­ies in the world’s largest on­col­o­gy re­search mar­ket.

This in­vest­ment strength­ens Pra­tia’s pres­ence in the Unit­ed States - and un­der­scores its com­mit­ment to ac­cel­er­at­ing new treat­ment de­vel­op­ment through clos­er col­lab­o­ra­tion with prac­tic­ing on­col­o­gists.

Ac­cord­ing to the Amer­i­can As­so­ci­a­tion for Can­cer Re­search, ap­prox­i­mate­ly 18.6 mil­lion can­cer sur­vivors were liv­ing in the U.S. as of Jan­u­ary 2025, while the World Health Or­ga­ni­za­tion es­ti­mates 3.7 mil­lion new can­cer cas­es an­nu­al­ly across Eu­rope.

“The part­ner­ship with Pra­tia en­ables us to de­liv­er a tru­ly ho­mo­ge­neous re­search ex­pe­ri­ence across con­ti­nents” - said Julio Peguero, MD, Pres­i­dent of P1 Tri­als. “By uni­fy­ing our sci­en­tif­ic rig­or, op­er­a­tional stan­dards, and pa­tient care mod­els, we’re build­ing a seam­less ear­ly-phase on­col­o­gy net­work that op­er­ates with the same pre­ci­sion and ex­cel­lence - from com­mu­ni­ty prac­tices in the U.S. to lead­ing re­search cen­ters across Eu­rope. This align­ment ac­cel­er­ates in­no­va­tion and en­sures pa­tients every­where gain faster ac­cess to to­mor­row’s ther­a­pies.”

The cre­ation of this uni­fied ear­ly-phase net­work aims to ad­dress the ur­gent glob­al need for faster de­vel­op­ment and wider ac­cess to in­no­v­a­tive ther­a­pies.

“P1’s mis­sion has al­ways been to bridge the gap be­tween re­search and every­day on­col­o­gy care, en­sur­ing pa­tients have ac­cess to pi­o­neer­ing treat­ments close to home” – adds Ron Caroz­za, Phar­mD, CEO, P1 Tri­als.  “We share the same val­ues as Pra­tia, and with their glob­al ex­per­tise and re­sources, we can ac­cel­er­ate this mis­sion even fur­ther. To­geth­er, we will bring the lat­est can­cer sci­ence di­rect­ly to pa­tients in their com­mu­ni­ties - faster."

Pra­tia, part of the Hu­mane­va Group, is one of Eu­rope’s largest clin­i­cal re­search site net­works, op­er­at­ing more than 100 re­search sites across mul­ti­ple ther­a­peu­tic ar­eas, with a strong fo­cus on on­col­o­gy. Pra­tia part­ners with spon­sors, CROs, and health­care providers to in­te­grate clin­i­cal re­search in­to every­day care and ex­pand ac­cess to in­no­v­a­tive treat­ments for di­verse pa­tient pop­u­la­tions. www.pra­tia.com

P1 Tri­als is a U.S.-based clin­i­cal re­search net­work spe­cial­iz­ing in ear­ly-phase on­col­o­gy stud­ies. By part­ner­ing with com­mu­ni­ty on­col­o­gy prac­tices, P1 Tri­als brings ad­vanced re­search op­por­tu­ni­ties di­rect­ly to pa­tients, en­abling faster ac­cess to next-gen­er­a­tion can­cer ther­a­pies close to home. www.p1tri­als.com

Hu­mane­va unites the clin­i­cal re­search ecosys­tem to im­prove the lives of can­cer pa­tients. The Group stands at the in­ter­sec­tion of pa­tient care and sci­en­tif­ic in­no­va­tion, de­liv­er­ing re­li­able clin­i­cal re­search da­ta that dri­ves bet­ter med­i­cine. It com­pris­es three com­ple­men­tary com­pa­nies, each ex­celling in its area of clin­i­cal re­search. To­geth­er, they form a clin­i­cal in­tel­li­gence in­fra­struc­ture con­nect­ing pa­tients, in­ves­ti­ga­tors, re­search cen­ters, and spon­sors through a seam­less flow of da­ta. www.hu­mane­va.com

Struc­ture Ther­a­peu­tic­s' GLP-1 pill cut pa­tients’ body weight by a place­bo-ad­just­ed av­er­age of 11.3% at around eight and a half months.

This is com­pet­i­tive with both Eli Lil­ly’s or­for­glipron and No­vo Nordisk’s oral for­mu­la­tion of We­govy, both of which are ex­pect­ed to reach mar­ket in the next few months.

Struc­ture said its da­ta for aleniglipron sup­port the start of Phase 3 tri­als. And the re­sults could al­so put the com­pa­ny on track to find a part­ner for the pill.

“We have a very safe drug in terms of off-tar­get safe­ty, best-in-class ef­fi­ca­cy … a clear path for Phase 3 and to mar­ket,” CEO Ray Stevens said on a we­b­cast Mon­day morn­ing to dis­cuss the re­sults. “We're look­ing for­ward to con­tin­u­ing dis­cus­sions with strate­gics, now that we have this da­ta. We know every­body's been wait­ing.”